Preventing peptide-induced anaphylaxis: addition of C-terminal amino acids to produce a neutral isoelectric point.

[1]  H. Mcdevitt,et al.  Severe anaphylactic reactions to glutamic acid decarboxylase (GAD) self peptides in NOD mice that spontaneously develop autoimmune type 1 diabetes mellitus , 2003, BMC Immunology.

[2]  A. Kay,et al.  Peptide-based vaccines in the treatment of specific allergy. , 2002, Current drug targets. Inflammation and allergy.

[3]  F. Finkelman,et al.  Anti-peptide autoantibodies and fatal anaphylaxis in NOD mice in response to insulin self-peptides B:9-23 and B:13-23. , 2002, The Journal of clinical investigation.

[4]  O. Lehoczky,et al.  [Reinduction of paclitaxel therapy after a successfully treated hypersensitivity reaction]. , 2002, Orvosi hetilap.

[5]  F. Finkelman,et al.  Pathways of anaphylaxis in the mouse. , 2002, The Journal of allergy and clinical immunology.

[6]  David Fear,et al.  The biology of IGE and the basis of allergic disease. , 2001, Annual review of immunology.

[7]  N. Sarvetnick,et al.  Vaccination with glutamic acid decarboxylase plasmid DNA protects mice from spontaneous autoimmune diabetes and B7/CD28 costimulation circumvents that protection. , 2001, Clinical immunology.

[8]  R. Pedotti,et al.  An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide , 2001, Nature Immunology.

[9]  A. Evans,et al.  Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial , 2000, Nature Medicine.

[10]  J. Frank,et al.  Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand , 2000, Nature Medicine.

[11]  L Heinemann,et al.  Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. , 2000, Diabetes care.

[12]  M. Rewers,et al.  Early expression of antiinsulin autoantibodies of humans and the NOD mouse: evidence for early determination of subsequent diabetes. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[13]  D. Umetsu,et al.  The safety and efficacy of ALLERVAX CAT in cat allergic patients. , 1999, Clinical immunology.

[14]  M. Manning,et al.  Preparation and in vitro characterization of gentamycin-impregnated biodegradable beads suitable for treatment of osteomyelitis. , 1998, Journal of pharmaceutical sciences.

[15]  D. MacGlashan,et al.  IgE-mediated desensitization in human basophils and mast cells. , 1998, Frontiers in bioscience : a journal and virtual library.

[16]  M. Manning,et al.  Hydrophobic Ion Pairing: Altering the Solubility Properties of Biomolecules , 1998, Pharmaceutical Research.

[17]  M. Manning,et al.  Drug delivery matrix containing native protein precipitates suspended in a poloxamer gel. , 1997, Journal of pharmaceutical sciences.

[18]  S. Galli,et al.  Systemic anaphylaxis in the mouse can be mediated largely through IgG1 and Fc gammaRIII. Assessment of the cardiopulmonary changes, mast cell degranulation, and death associated with active or IgE- or IgG1-dependent passive anaphylaxis. , 1997, The Journal of clinical investigation.

[19]  K. Shokat,et al.  Intravenous injection of soluble antigen induces thymic and peripheral T-cells apoptosis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[20]  D. Wegmann,et al.  Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[21]  H. Weiner,et al.  Induction of anergy or active suppression following oral tolerance is determined by antigen dosage. , 1994, Proceedings of the National Academy of Sciences of the United States of America.